Logo

MOVE

Movano Inc.

MOVE

Movano Inc. • NASDAQ
$10.50 ▼ -1.32% (-0.14)
Market Cap $7.97 M
52w High $69.68
52w Low $4.67
Dividend Yield 0%
P/E -0.48
Volume 13.45K
Outstanding Shares 758.73K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $80K ▼ $2.391M ▼ $-4.029M ▼ -5.036K% ▼ $-0.052 ▲ $-2.498M ▲
Q2-2025 $103K ▼ $3.001M ▼ $-3.225M ▲ -3.131K% ▼ $-0.41 ▲ $-3.169M ▲
Q1-2025 $206K ▲ $4.802M ▲ $-5.178M ▼ -2.514K% ▲ $-0.73 ▼ $-5.2M ▼
Q4-2024 $111K ▲ $4.236M ▼ $-4.616M ▲ -4.159K% ▲ $-0.077 ▲ $-4.578M ▲
Q3-2024 $50K $6.584M $-7.201M -14.402K% $-0.11 $-7.33M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $2M ▼ $5.557M ▼ $7.258M ▲ $-1.701M ▼
Q2-2025 $2.109M ▼ $5.66M ▼ $4.023M ▼ $1.637M ▼
Q1-2025 $4.357M ▼ $7.766M ▼ $4.532M ▲ $3.234M ▼
Q4-2024 $7.902M ▼ $11.32M ▼ $3.965M ▼ $7.355M ▼
Q3-2024 $11.272M $15.067M $4.816M $10.251M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-4.029M ▼ $-1.609M ▲ $0 $1.5M ▲ $-109K ▲ $-1.609M ▲
Q2-2025 $-3.225M ▲ $-3.096M ▲ $0 $848K ▲ $-2.248M ▲ $-3.096M ▲
Q1-2025 $-5.178M ▼ $-4.303M ▲ $0 ▲ $758K ▼ $-3.545M ▼ $-4.303M ▲
Q4-2024 $-4.616M ▲ $-4.555M ▲ $-5K ▼ $1.19M ▲ $-3.37M ▲ $-4.56M ▲
Q3-2024 $-7.201M $-5.675M $3K $76K $-5.596M $-5.672M

Five-Year Company Overview

Income Statement

Income Statement Movano is still in the “pre‑revenue” stage: it has effectively no sales yet and has been running steady losses each year. The size of the losses has been fairly consistent, with a slight recent improvement, but the big picture is that the business is spending on development and operations without yet generating meaningful income. This is typical of an early-stage medical device and tech company, but it also means results are highly dependent on future product adoption rather than current earnings strength.

Balance Sheet

Balance Sheet The balance sheet is very light, with a small asset base that is mostly cash and virtually no debt in recent years. Equity has hovered around break-even, at times slipping negative and then recovering, which signals that the company has been burning through capital and periodically recapitalizing. Overall, the financial cushion looks thin: leverage is low, which reduces financial risk, but the limited asset and equity base means there is not a lot of buffer if funding conditions tighten or commercialization takes longer than expected.

Cash Flow

Cash Flow Cash flow has consistently been negative, driven by operating losses and ongoing spending on development and overhead. Free cash flow is also negative, and there is essentially no meaningful investment in physical assets, which underlines that most spending is on people, research, and product development rather than factories or equipment. The business depends on external capital to fund operations until products can generate meaningful cash inflows. This reliance on funding, combined with a modest cash balance, is an important risk factor to keep in mind.

Competitive Edge

Competitive Edge Movano’s health-tech position rests on two main pillars: a women-focused smart ring (Evie) and its proprietary radio-frequency technology for non-invasive vital sign monitoring. The women-first design, subscription-free model, and early FDA clearance for a pulse oximetry feature help it stand out from general wellness rings. Its patented RF approach for cuffless blood pressure and potential non-invasive glucose monitoring could be a strong differentiator if it proves accurate and scalable. At the same time, the wearables space is crowded with well-funded competitors, and the company is now being folded into a broader AI infrastructure business, which introduces uncertainty about how much focus and resources will remain dedicated to the health device segment. The moat is promising on paper but not yet proven in the market.

Innovation and R&D

Innovation and R&D Innovation is the clear strength of Movano’s story. It has developed a specialized women’s health ring, built an AI-driven insight platform around it, and made meaningful progress on miniaturizing its RF system-on-a-chip for future monitoring applications. FDA clearance for one feature is a significant validation step, and ongoing clinical work on blood pressure and glucose monitoring shows ambition to move beyond wellness into true medical-grade data. However, this is a long, costly road: more trials, regulatory submissions, and product refinement will be needed before the technology can be widely adopted in medical settings. The recent merger and strategic pivot toward AI infrastructure also adds execution risk around how consistently R&D in health-tech will be funded and prioritized.

Summary

Movano is an early-stage, innovation-heavy company with almost no current revenue, persistent but manageable-sized losses, and a very lean balance sheet funded largely by external capital. Its core health-tech assets—the Evie Ring and the proprietary RF platform—offer a differentiated angle in women’s health and non-invasive monitoring, backed by patents and early regulatory traction. On the other hand, commercialization is still in its infancy, cash burn is ongoing, and the strategic shift via the Corvex merger introduces both opportunity (access to broader tech and capital) and uncertainty (how the health division will be positioned, funded, or potentially separated). The overall picture is a high-uncertainty, high-dependence-on-execution story where future value will hinge on successful product adoption, clinical validation, and clear strategic focus within the new corporate structure.

NEWS

November 27, 2025 · 11:17 PM UTC

HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the Merger - GIFI, MOVE, NUVSF and ORBI

Read more

November 27, 2025 · 6:42 PM UTC

Halper Sadeh LLC Encourages MOVE and GIFI Shareholders to Contact the Firm to Discuss Their Rights

Read more

November 12, 2025 · 7:55 AM UTC

MOVE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Movano Inc. is Fair to Shareholders

Read more

November 10, 2025 · 7:30 AM UTC

CORVEX TO GO PUBLIC IN ALL-STOCK MERGER WITH MOVANO, CREATING A PURE-PLAY PLATFORM FOR SECURE AI INFRASTRUCTURE AND HIGH-PERFORMANCE INFERENCE

Read more

October 8, 2025 · 8:30 AM UTC

Movano Health Announces Reverse Stock Split

Read more